Drugs that contain Plazomicin Sulfate
1. List of Zemdri drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9688711 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(5 years from now) | |
| US8383596 | CIPLA USA | Antibacterial aminoglycoside analogs |
Jun, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266919 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(5 years from now) | |
| US8822424 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(5 years from now) | |
Do you want to check out ZEMDRI patents from before 2022?
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 25, 2023 |
| Generating Antibiotic Incentives Now (GAIN) | Jun 25, 2028 |
NCE-1 date: 2027-06-26
Market Authorisation Date: 25 June, 2018
Treatment: Method of using plazomicin to treat bacterial infections
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
ZEMDRI family patents
11
United States
2
China
2
Japan
2
European Union
1
Spain
1
Denmark
1
Poland
1
Brazil
1
Canada
1
EA
1
Croatia
1
Korea, Republic of
1
Cyprus
1
Israel
1
Portugal
1
Taiwan
1
Mexico
1
Australia
1
Lithuania
1
Slovenia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic